Advertisement

Topics

NetScientific announces first sale of point-of care test from portfolio company

02:30 EST 15 Feb 2018 | Proactive Investors

The NEATstik test, registered with a CE mark in the second half of 2017, was sold to a research laboratory conducting a respiratory clinical trial for a pharmaceutical company

Original Article: NetScientific announces first sale of point-of care test from portfolio company

NEXT ARTICLE

More From BioPortfolio on "NetScientific announces first sale of point-of care test from portfolio company"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...